Pleased to announce the licensing agreement with Pearl Therapeutics for SimpleCTMS

We are very pleased to announce that Pearl Therapeutics, Inc., a US based biopharmaceutical company, has selected SimpleCTMS as their CTMS vendor to optimize the management of their global clinical studies.  

The initial Pearl deployment includes multiple Phase II global studies in which SimpleCTMS will be deployed for study startup planning and ongoing study tracking. SimpleCTMS will improve data transparency across service providers, and integrate with other key eClinical systems utilized by Pearl.

Read the full release on Marketwire.